According to a revised pipeline analysis, six Alzheimer's drugs will conclude Phase III trials in 2017, bringing much-needed solutions to families in the near future. The late-stage pipeline offers hope to 5.5 million Americans with the disease and their caregivers.
The project aims to develop inclusive research engagement networks to recruit underrepresented populations into brain health research. Key findings include the development of a sustainable online network to facilitate minority research engagement and knowledge sharing.
ResearchersAgainstAlzheimer's report reveals 57 new Alzheimer's drugs in Phase II testing, with nearly twice as many mechanisms of action being tested as in Phase III clinical trials. The analysis calls for changes to clinical trial infrastructure and endpoints to ensure rapid recruitment and effective testing.